Novartis AG (NVSEF)
| Market Cap | 232.39B |
| Revenue (ttm) | 53.22B |
| Net Income (ttm) | 12.86B |
| Shares Out | n/a |
| EPS (ttm) | 6.38 |
| PE Ratio | 18.07 |
| Forward PE | 14.21 |
| Dividend | 3.97 (3.42%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 100 |
| Average Volume | 4,185 |
| Open | 115.17 |
| Previous Close | 116.13 |
| Day's Range | 115.13 - 118.00 |
| 52-Week Range | 94.70 - 123.55 |
| Beta | 0.53 |
| RSI | 52.00 |
| Earnings Date | Jul 17, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsNews
Divi’s Laboratories shares in focus after Novartis and MSN settle on Entresto 659 patent
Shares of Divi’s Laboratories are in focus after an update in the legal proceedings surrounding Novartis’ heart failure drug Entresto. Novartis and MSN Laboratories have reached a settlement on the ‘6...
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis AG NVS on Thursday released results from APPULSE-PNH, a Phase 3B study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with paroxysma...
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patien...
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co . (NYSE: BMY) entered into a co-development and co-commercialization agreement . The pact focuses on BioNTech’s investigational bispecific an...
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a ...
Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial
Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormon...
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
The U.S. Food and Drug Administration (FDA) on Wednesday approved Alcon Plc’s (NYSE: ALC) Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for signs and symptoms of Dry Ey...
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to a...
If I Could Only Buy 2 Dividend Stocks Right Now (May 2025 Edition)
I've added Novo Nordisk and Novartis to boost The Dividend Income Accelerator's healthcare allocation and global diversification, reducing overall risk and volatility. Both companies are attractively ...
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
Basel, May 15, 2025 – Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncol...
Incyte and Novartis settle royalties dispute related to Jakafi
GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion
GSK plc (NYSE: GSK) on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa . Under the agreement, GSK will pay up to $2 billion in total cash consideration. This include...
Greece needs urgent cardiovascular disease action plan, says leading health executive
Greek use of interoperable digital tools and secure data platforms such as the EHDS could boost early detection and personalised treatment, while advancing CVD care, a senior Novartis executive tells ...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.
Novartis to keep making malaria drugs if orders dry up amid aid cuts
Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told Reuters...
Pharma Worries Shift to Prices From Trade. Trump's Next Plan Could Sink Stocks.
The president says big news about drug pricing is coming next week.
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
China sees global turmoil as opportunity to be ‘business friendly’, says Novartis chief
Vas Narasimhan argues potential US tariffs on pharma industry are not ‘sensible’
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025 , NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephien...
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...